Latest News and Press Releases
Want to stay updated on the latest news?
-
Celsion Corporation’s GEN-1 IL-12 Program in Advanced Ovarian Cancer to be Featured in Poster Presentation Chief Science Officer Dr. Khursheed Anwer to Present and Participate in Two Panel...
-
LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
-
Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation on Celsion’s Ongoing Work with DNA-based Vaccines LAWRENCEVILLE, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Celsion...
-
LAWRENCEVILLE, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
-
VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 ...
-
A Quorum Has Been Achieved to Reconvene Annual Meeting on Thursday June 10, 2021 Polls Remain Open, Shareholders are Urged to Vote LAWRENCEVILLE, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- Celsion...
-
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
-
LAWRENCEVILLE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...
-
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement To date 34 patients, or...